Capecitabine Tablets
Phase 3
Capecitabine Tablets is one of 73 therapeutic programs targeting Adenocarcinoma. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
72
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
337 competitors in Adenocarcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Taxotere
AAvyxa
Phase 3
Beyfortus
BeiGenePhase 3
Iressa
AstraZenecaPhase 3
Ellence
PfizerPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
DATROWAY
Daiichi SankyoPhase 3
Paraplatin
AAvyxa
Phase 3
Camptosar
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Triple-Negative Breast Cancer1 trial
Adenocarcinoma1 trial
A Randomized, Open-Label, Multicenter Phase III Study of Tecotabart Vedotin Plus Tislelizumab Versus Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With CLDN18.2-Positive, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 3·NCT07385703·752 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Capecitabine Tablets. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]